HIV Preventive Vaccines: Progress to Date

Drugs

Volumn 50, Issue 5, 1995, Pages 792-804

  Esparza, José ^a   Osmanov, Saladin ^a   Heyward, William L ^a  

^a WORLD HEALTH ORGANIZATION   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS VACCINE; NEUTRALIZING ANTIBODY; VIRUS ANTIBODY;

CHIMPANZEE; CLINICAL TRIAL; CYTOTOXIC T LYMPHOCYTE; DRUG EFFICACY; DRUG TOLERANCE; GENETIC VARIABILITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION RESISTANCE; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; REVIEW; SURVIVAL TIME; VACCINATION;

AIDS VACCINES; ANIMAL; CLINICAL TRIALS; HIV INFECTIONS; HIV-1; HUMAN;

EID: 0028827556     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/00003495-199550050-00003     Document Type: Review

References (154)

1. Slowing the spread of HIV: agenda for the 1990s
2. Global estimates and epidemiology of HIV infections and AIDS
3. Planning for HIV vaccine trials: the World Health Organization perspective
4. The development and evaluation of HIV vaccines
5. Clinical trials of experimental AIDS vaccines
6. Scientific and social issues of human immunodeficiency virus vaccine development
7. Vaccinology, immunology, and comparative pathogenesis of measles in the quest for a preventative against AIDS
8. HIV vaccine development: a progress report (NIH Conference)
9. Vaccines against human immunodeficiency virus — progress and prospects
10. Anti-HIV vaccines: current status and future development
11. Reexamining AIDS research priorities
12. Prevention of HIV/AIDS with vaccines
13. Cell-mediated immunity in HIV infection
14. AIDS research shifts to immunity
15. Cytokine patterns during the progression to AIDS
16. The immunopathogenesis of human immunodeficiency virus infection
17. Multifactorial nature of human immunodeficiency virus disease: implications for therapy
18. HIV pathogenesis and long term survival
19. Resistance to HIV infection
20. Cell-mediated immune response to human immunodeficiency virus (HIV) type 1 in seronegative homosexual men with recent sexual exposure to HIV-1
21. HIV-specific T-helper activity in seronegative health care workers exposed to contaminated blood
22. Occurrence of human immunodeficiency virus type 1 (HIV-1)-specific cytolytic T cell activity in apparently uninfected children born to HIV-1 infected mothers
23. Alloimmunization to prevent AIDS?
24. HIV-specific cytotoxic T-cell activity in an HIV-exppsed but uninfected infant
25. Alloimmunization as an AIDS vaccine?
26. Human immunodeficiency virus infection among high-risk seronegative prostitutes in Nairobi
27. Primary human immunodeficiency virus type 1 infection: review of pathogenesis and early treatment intervention in human and animal retrovirus infections
28. Shutting down HIV
29. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome
30. Major expansion of CD8+ T cells with a predominant Vβ usage during the primary immune response to HIV
31. Development of the anti-gp120 antibody response during seroconversion to human immunodeficiency virus type 1
32. Lessons from people with nonprogressive HIV infection
33. Studies in subjects with long-term nonprogressive human immunodeficiency virus infection
34. Quantitation of HIV-1 RNA in plasma predicts outcome after seroconversion
35. Variable course of primary simian immunodeficiency virus infection in lymph nodes: relation to disease progression
36. Prolonged clinical latency and survival of macaques given a whole inactivated simian immunodeficiency virus vaccine
37. A new goal: preventing disease, not infection
38. Protection from HIV infection or AIDS?
39. A strategy for prophylactic vaccines against HIV
40. Massive covert infection of helper T lymphocytes and macrophages by HIV during the incubation period of AIDS
41. HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease
42. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection
43. Viral dynamics in human immunodeficiency virus type 1 infection
44. Determinants of HIV disease progression among homosexual men registered in the tricontinental seroconverter study
45. Non-progression in HIV infection
46. Long-term HIV-1 infection without immunological progression
47. Virologic and immunologic characterization of long-term survivors of human immunodeficiency virus type 1 infection
48. Longitudinal analysis of the humoral response to human immunodeficiency virus type 1 (HIV-1) gp160 epitopes in rapidly progressing and nonprogressing HIV-1-infected subjects
49. Characterization of nef sequences in long-term survivors of human immunodeficiency virus type 1 infection
50. Absence of intact nef sequences in a long-term survivor with nonprogressive HIV-1 infection
51. Neutralization of divergent human immunodeficiency virus type 1 variants and primary isolates by IAM-41-2F5, an anti-gp41 human monoclonal antibody
52. Native oligomeric human immunodeficiency virus type 1 envelope glycoprotein elicits diverse monoclonal antibody reactivities
53. Immunization with a soluble CD4-gp120 complex preferentially induces neutralizing anti-human immunodeficiency virus type 1 antibodies directed to conformation-dependent epitopes of gp120
54. Synergistic neutralization of human immunodeficiency virus type 1 by combinations of human monoclonal antibodies
55. Antibodies to discontinuous or conformationally sensitive epitopes on the gp120 glycoprotein of human immunodeficiency virus type 1 are highly prevalent in sera of infected humans
56. A conserved neutralizing epitope on gp41 human immunodeficiency virus type 1
57. HIV-type 1 variation in World Health Organization-sponsored vaccine evaluation sites: genetic screening, sequence analysis, and preliminary biological characterization of selected viral strains
58. Rapid genetic characterization of HIV strains from four World Health Organization-sponsored vaccine evaluation sites using a heteroduplex mobility assay
59. Identification of an env G subtype and heterogeneity of HIV-1 strains in the Russian Federation and Belarus
60. The serologic significance of F viral genotype for human immunodeficiency virus type 1 epidemic
61. Characterization of human immunodeficiency virus type 1 isolates from children in Rumania: identification of a hew envelope subtype
62. Genetic variation of HIV type 1 in four World Health Organization-sponsored vaccine evaluation sites: generation of functional envelope (glycoprotein 160) clones representative of sequence subtypes A, B, C, and E
63. Molecular phylogeny of part of the env gene of HIV-1 strains isolated in Côte d’Ivoire
64. The World Health Organization Global Programme on AIDS proposal for standardization of HIV sequence nomenclature
65. Phylogenetic analysis of gag genes from seventy international HIV-1 isolates provided evidence for multiple genotypes
66. Genetic analysis of HIV-1 isolates from Brazil reveals the presence of two distinct genotypes
67. Genetic diversity of the envelope glycoprotein from human immunodeficiency virus type 1 isolates of African origin
68. Identification of human immunodeficiency virus type 1 envelope genes recombinant between subtypes B and F in two epidemiological linked individuals from Brazil
69. Origins and diversity of human immunodeficiency viruses
70. A new subtype of human immunodeficiency virus type 1 (MVP-5180) from Cameroon
71. IIIb in sera of African and Belgian HIV-1-infected individuals
72. ANT-70 isolate in human sera from different geographic regions
73. Genomic cloning and complete sequence analysis of a highly divergent African human immunodeficiency virus isolate
74. Prevalence of HIV-1 subtype O infection in Cameroon: preliminary findings
75. Serotyping HIV type 1 by antibody binding to the V3 loop: relationship to viral genotype
76. Antigenic variation and serotyping of HIV type 1 from four World Health Organization-sponsored HIV vaccine sites
77. The World Health Organization network for HIV isolation and characterization
78. Antigenic variation and serotyping of HIV type 1 from four World Health Organization-sponsored HIV vaccine sites
79. Exploration of antigenic variation in gp120 from clades A through F of human immunodeficiency virus type 1 by using monoclonal antibodies
80. Two antigenically distinct subtypes of human immunodeficiency virus type 1: viral genotype predicts neutralization serotype
81. Syncytium-inducing and non-syncytium inducing capacity of human immunodeficiency virus type 1 subtypes other than B: phenotypic and genotypic characteristics
82. Standard conditions of virus isolation reveal biological variability of HIV type 1 in different regions of the world
83. Genotypic and phenotypic characterization of HIV-1 in patients with primary infection
84. Cryptic nature of envelope V3 region epitopes protects primary monocytotropic human immunodeficiency virus type 1 from antibody neutralization
85. Neutralization sensitivity of human immunodeficiency virus type 1 is determined in part by the cell in which the virus is propagated
86. Nonhuman primate models for AIDS
87. Annual update survey of worldwide HIV, SIV, and SHIV challenge studies in vaccinated nonhuman primates
88. Anti-cell antibody in macaques
89. Cellular proteins bound to immunodeficiency viruses: implications for pathogenesis and vaccines
90. Vaccine protection of chimpanzees against challenge with HIV-1-infected peripheral blood mononuclear cells
91. Protection of chimpanzees against heterologous HIV-1 challenge
92. Serological responses to candidate AIDS vaccines
93. Protection of rhesus macaques from SIV infection by immunization with different experimental SIV vaccines
94. Immune response of rhesus macaques to recombinant simian immunodeficiency virus gp130 does not protect from challenge infection
95. Incomplete protection, but not suppression of virus burden, elicited by subunit simian immunodeficiency virus vaccines
96. Long-standing protection of macaques against cell-free HIV-2 with a HIV-2 iscom vaccine
97. Long term high titer neutralizing activity induced by octameric synthetic HIV-1 antigen
98. Hybrid human immunodeficiency virus gag particles as an antigen carrier system: induction of cytotoxic T-cell and humoral responses by a gag: V3 fusion
99. Immunization of human HIV-seronegative volunteers with recombinant p17/p24: Ty virus-like particles elicits HIV-1 p24-specific cellular and humoral immune responses
100. gag/V3 chimeric vaccinia viruses
101. gag protein: understanding the mechanism of virus assembly as a basis for the development of novel therapeutics and vaccines
102. Use of new vectors for the development of vaccines
103. Engineering poliovirus as a vaccine vector for the expression of diverse antigens
104. Immunogenicity of Adeno-HIV vaccines in chimpanzees
105. Highly attenuated poxvirus vector strains, NY VAC and ALVAC, in retrovirus vaccine development
106. Characterization and primary structure of a human immunodeficiency virus type 1 (HIV-1) neutralization domain as presented by a poliovirus type 1/HIV-1 chimera
107. Protective effects of a live attenuated SIV vaccine with a deletion in the nef gene
108. HIV with multiple gene deletions as a live attenuated vaccine for AIDS
109. Upstream U3 sequences in simian immunodeficiency virus are selectively deleted in vivo in the absence of an intact nef gene
110. The role of upstream U3 sequences in the pathogenesis of simian immunodeficiency virus-induced AIDS in rhesus monkeys
111. Protection of monkeys against SIV infection with live attenuated viruses
112. A radical strategy for development of a vaccine against HIV-1
113. Live attenuated immunodeficiency viruses: interesting scientific tools or vaccines of the future?
114. Controversies in science: a live-virus AIDS vaccine? Not yet, it is too early to consider use of a live-attenuated virus vaccine against HIV-1
115. At conference, hope for success is further attenuated
116. Controversies in science: a live-virus AIDS vaccine? Yes, it is time to consider use of a live-attenuated virus vaccine against HIV-1
117. Feasibility of developing live attenuated HIV vaccines: conclusions and recommendations
118. Nucleic acid immunization: a prophylactic gene therapy?
119. Immunization with polynucleotides: a novel approach to vaccination
120. DNA vaccines: protective immunizations by parenteral, mucosal, and gene-gun inoculations
121. Intradermal gene immunization: the possible role of DNA uptake in the induction of cellular immunity to viruses
122. Safety considerations for nucleic acid vaccines
123. Gene vaccines, a new approach to immunization
124. Introduction: nucleic acid vaccines, WHO, Geneva, 17–18 May 1994
125. Regulatory considerations for nucleic acid vaccines
126. Gene inoculation generates immune responses against human immunodeficiency virus type 1
127. Evaluation of candidate HIV-1 prophylactic vaccines in phase I/II trials
128. IIB rgp120 subunit vaccine
129. Comparison of the immune response to recombinant gp120 in humans and chimpanzees
130. Neutralizing antibodies to HIV-1 in seronegative volunteers immunized with recombinant gp120 from the MN strain of HIV-1
131. SF2 gp120 subunit vaccine combined with MF59 adjuvant with or without muramyl tripeptide dipalmitoyl phosphatidylethanolamine in non-HIV-infected human volunteers
132. Safety and immunogenicity of a fully glycosylated recombinant gp160 human immunodeficiency virus type 1 vaccine in subjects at low risk of infection
133. Human CD4+ cytolytic T lymphocyte responses to a human immunodeficiency virus type 1 gp160 subunit vaccine
134. Combined antigen regimes for vaccination against HIV
135. Vaccine clinical trials: chairman’s overview
136. Persisting human immunodeficiency virus type 1 gp160-specific human T lymphocyte responses including CD8+ cytotoxic activity after receipt of envelope vaccines
137. Determinants of antibody response after recombinant gp160 boosting in vaccinia-naive volunteers primed with gp160-recombinant vaccinia virus
138. Immune responses elicited by recombinant vaccinia-human immunodeficiency virus (HIV) envelope and HIV envelope protein: analysis of the durability of responses and effect of repeated boosting
139. R vaccine: the advantages of controlled release microparticles
140. HIV infection in vaccinated volunteers
141. Will media reports KO upcoming real-life trials?
142. AIDS vaccines: are we ready for human efficacy trials?
143. Considerations for commencement of HIV vaccine efficacy trials: a working group summary
144. Scientific and public health rationale for HIV vaccine efficacy trials
145. US Panel votes to delay real-world vaccine trials
146. International HIV/AIDS vaccine trials: expectations of host countries
147. Development of WHO-sponsored sites for HIV vaccine evaluation
148. Preparation for efficacy trials of preventive HIV candidate vaccines: the role of the World Health Organization
149. Preparation for phase III HIV vaccine efficacy trials: methods for the determination of HIV incidence
150. Behavioral research contributions to planning and conducting HIV vaccine efficacy trials
151. Ethical, behavioural, and social aspects of HIV vaccine trials in developing countries